NRX Pharmaceuticals Inc logo

NRXP

NRX Pharmaceuticals Inc

$0.73

Earnings Summary

Revenue
$0Mn
Net Profits
$-13.45Mn
Net Profit Margins
-Inf%

Highlights

Revenue:

NRX Pharmaceuticals Inc’s revenue jumped NaN% since last year same period to $0Mn in the Q1 2022. On a quarterly growth basis, NRX Pharmaceuticals Inc has generated NaN% jump in its revenue since last 3-months.

Net Profits:

NRX Pharmaceuticals Inc’s net profit fell -3010.43% since last year same period to $-13.45Mn in the Q1 2022. On a quarterly growth basis, NRX Pharmaceuticals Inc has generated -100.07% fall in its net profits since last 3-months.

Net Profit Margins:

NRX Pharmaceuticals Inc’s net profit margin jumped NaN% since last year same period to -Inf% in the Q1 2022. On a quarterly growth basis, NRX Pharmaceuticals Inc has generated NaN% jump in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the NRX Pharmaceuticals Inc post its latest quarter earnings

EPS Estimate Current Year
-0.1

Highlights

EPS Estimate Current Year:

NRX Pharmaceuticals Inc’s earning per share (EPS) estimates for the current year stand at -0.1.

Key Ratios

Key ratios of the NRX Pharmaceuticals Inc post its Q1 2022 earnings

Earning Per Share (EPS)
-0.21
Return on Assets (ROA)
-2.32
Return on Equity (ROE)
-4.26
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

NRX Pharmaceuticals Inc’s earning per share (EPS) jumped 96.76% since last year same period to -0.21 in the Q1 2022. This indicates that the NRX Pharmaceuticals Inc has generated 96.76% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. NRX Pharmaceuticals Inc’s return on assets (ROA) stands at -2.32.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. NRX Pharmaceuticals Inc’s return on equity (ROE) stands at -4.26.

Dividend Per Share (DPS):

NRX Pharmaceuticals Inc declared 0 dividend per share during the earnings announcement for Q1 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2021-08-16
0
-0.4
-Inf%

Company Information

Big Rock Partners is a blank check company formed for the purpose of entering into a merger, stock exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more businesses or entities. Big Rock Partners' management team includes Richard Ackerman, Chairman, President, and Chief Executive Officer, and Bennett Kim, Chief Financial Officer, Chief Investment Officer, Corporate Secretary and Director.

Organisation
NRX Pharmaceuticals Inc
Headquarters
Delray Beach, Florida, US
Employees
2